Search research articles
Contact Us
Filters
Showing results (21-30 of 112) with videos related to
Page
of 12
Sort By:
Cancer
|
May 15, 1982
Ocular side effects of cancer chemotherapy
M Vizel, M W Oster
International Journal of Cell Cloning
|
January 1, 1989
Role of colony-stimulating factors in the biology of acute myelogenous leukemia
W Oster, R Mertelsmann, F Herrmann
Medical and Pediatric Oncology
|
January 1, 1981
Myocardial injury immediately following adriamycin administration
M W Oster, T J Rakowski
Biotechnology Therapeutics
|
January 1, 1991
Interleukin-1, characterization of the molecule, functional activity, and clinical implications
D Brazel, S Nakanishi, W Oster
Haematology and Blood Transfusion
|
January 1, 1990
Mechanisms of autocrine and paracrine growth control in acute myelogenous leukemia
W Oster, R Mertelsmann, F Hermann
Anti-Cancer Drugs
|
January 1, 1997
Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro
S Fulda, W Oster, F Berthold
Pharmacology & Therapeutics
|
October 1, 1991
Adjuvant therapy with recombinant interleukin-3 and granulocyte-macrophage colony-stimulating factor
G Schulz, D Krumwieh, W Oster
Behring Institute Mitteilungen
|
December 1, 1991
Clinical evaluation of erythropoietin (EPO) in oncology
W Oster, F Schindel, H Heinrichs
Contributions to Nephrology
|
January 1, 1991
Treatment of patients with anemia of malignancy with recombinant human erythropoietin
F Herrmann, W Oster, R Mertelsmann
Klinische Padiatrie
|
July 1, 1990
Control of blast cell proliferation and differentiation in acute myelogenous leukemia by soluble polypeptide growth factors
F Herrmann, W Oster, R Mertelsmann
Page
of 12
Search research articles
Search
Showing results (21-30 of 112) with videos related to
Sort By:
Page
of 12
Cancer
|
May 15, 1982
Ocular side effects of cancer chemotherapy
M Vizel, M W Oster
International Journal of Cell Cloning
|
January 1, 1989
Role of colony-stimulating factors in the biology of acute myelogenous leukemia
W Oster, R Mertelsmann, F Herrmann
Medical and Pediatric Oncology
|
January 1, 1981
Myocardial injury immediately following adriamycin administration
M W Oster, T J Rakowski
Biotechnology Therapeutics
|
January 1, 1991
Interleukin-1, characterization of the molecule, functional activity, and clinical implications
D Brazel, S Nakanishi, W Oster
Haematology and Blood Transfusion
|
January 1, 1990
Mechanisms of autocrine and paracrine growth control in acute myelogenous leukemia
W Oster, R Mertelsmann, F Hermann
Anti-Cancer Drugs
|
January 1, 1997
Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro
S Fulda, W Oster, F Berthold
Pharmacology & Therapeutics
|
October 1, 1991
Adjuvant therapy with recombinant interleukin-3 and granulocyte-macrophage colony-stimulating factor
G Schulz, D Krumwieh, W Oster
Behring Institute Mitteilungen
|
December 1, 1991
Clinical evaluation of erythropoietin (EPO) in oncology
W Oster, F Schindel, H Heinrichs
Contributions to Nephrology
|
January 1, 1991
Treatment of patients with anemia of malignancy with recombinant human erythropoietin
F Herrmann, W Oster, R Mertelsmann
Klinische Padiatrie
|
July 1, 1990
Control of blast cell proliferation and differentiation in acute myelogenous leukemia by soluble polypeptide growth factors
F Herrmann, W Oster, R Mertelsmann
Page
of 12